Axim Biotechnologies (OTC: AXIM)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Axim Biotechnologies Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Axim Biotechnologies Company Info
News & Analysis
These pot stocks are bad news for investors.
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
These cannabinoid-based drug developers have recently gone up in smoke.
Despite big gains, these pot stocks appear to be headed in diverging directions.
Despite its big gains, this pot stock remains a going concern.
Pot stocks' average return exceeds 23 times the S&P 500's performance over the past year. But is it sustainable?
Axim Biotechnologies was the hottest marijuana stock of 2016, but it's cooled down considerably so far this year. Here's what you need to know about this former highflier.
There were 20,101 opioid-related overdose deaths in 2015, compared to zero overdose-related deaths for marijuana that year.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.